Enabling individualized therapy through nanotechnology

Jason H. Sakamoto, Anne L. van de Ven, Biana Godin, Elvin Blanco, Rita E. Serda, Alessandro Grattoni, Arturas Ziemys, Ali Bouamrani, Ye Hu, Shivakumar I. Ranganathan, Enrica De Rosa, Jonathan O. Martinez, Christine A. Smid, Rachel M. Buchanan, Sei Young Lee, Srimeenakshi Srinivasan, Matthew Landry, Anne Meyn, Ennio Tasciotti, Xuewu LiuPaolo Decuzzi, Mauro Ferrari

Research output: Contribution to journalReview article

129 Citations (Scopus)

Abstract

Individualized medicine is the healthcare strategy that rebukes the idiomatic dogma of 'losing sight of the forest for the trees'. We are entering a new era of healthcare where it is no longer acceptable to develop and market a drug that is effective for only 80% of the patient population. The emergence of "-omic" technologies (e.g. genomics, transcriptomics, proteomics, metabolomics) and advances in systems biology are magnifying the deficiencies of standardized therapy, which often provide little treatment latitude for accommodating patient physiologic idiosyncrasies. A personalized approach to medicine is not a novel concept. Ever since the scientific community began unraveling the mysteries of the genome, the promise of discarding generic treatment regimens in favor of patient-specific therapies became more feasible and realistic. One of the major scientific impediments of this movement towards personalized medicine has been the need for technological enablement. Nanotechnology is projected to play a critical role in patient-specific therapy; however, this transition will depend heavily upon the evolutionary development of a systems biology approach to clinical medicine based upon "-omic" technology analysis and integration. This manuscript provides a forward looking assessment of the promise of nanomedicine as it pertains to individualized medicine and establishes a technology "snapshot" of the current state of nano-based products over a vast array of clinical indications and range of patient specificity. Other issues such as market driven hurdles and regulatory compliance reform are anticipated to "self-correct" in accordance to scientific advancement and healthcare demand. These peripheral, non-scientific concerns are not addressed at length in this manuscript; however they do exist, and their impact to the paradigm shifting healthcare transformation towards individualized medicine will be critical for its success.

Original languageEnglish (US)
Pages (from-to)57-89
Number of pages33
JournalPharmacological Research
Volume62
Issue number2
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

Nanotechnology
Precision Medicine
Delivery of Health Care
Systems Biology
Technology
Nanomedicine
Therapeutics
Metabolomics
Clinical Medicine
Genomics
Proteomics
Compliance
Medicine
Genome
Pharmaceutical Preparations
Population

Keywords

  • -Omic technologies
  • Implantable device
  • Individualized therapy
  • Nanomedicine
  • Nanoparticle
  • Nanotechnology
  • Nanovector
  • Personalized medicine
  • Regulatory process
  • Systems biology
  • Tissue engineering

ASJC Scopus subject areas

  • Pharmacology

Cite this

Sakamoto, J. H., van de Ven, A. L., Godin, B., Blanco, E., Serda, R. E., Grattoni, A., ... Ferrari, M. (2010). Enabling individualized therapy through nanotechnology. Pharmacological Research, 62(2), 57-89. https://doi.org/10.1016/j.phrs.2009.12.011

Enabling individualized therapy through nanotechnology. / Sakamoto, Jason H.; van de Ven, Anne L.; Godin, Biana; Blanco, Elvin; Serda, Rita E.; Grattoni, Alessandro; Ziemys, Arturas; Bouamrani, Ali; Hu, Ye; Ranganathan, Shivakumar I.; De Rosa, Enrica; Martinez, Jonathan O.; Smid, Christine A.; Buchanan, Rachel M.; Lee, Sei Young; Srinivasan, Srimeenakshi; Landry, Matthew; Meyn, Anne; Tasciotti, Ennio; Liu, Xuewu; Decuzzi, Paolo; Ferrari, Mauro.

In: Pharmacological Research, Vol. 62, No. 2, 01.08.2010, p. 57-89.

Research output: Contribution to journalReview article

Sakamoto, JH, van de Ven, AL, Godin, B, Blanco, E, Serda, RE, Grattoni, A, Ziemys, A, Bouamrani, A, Hu, Y, Ranganathan, SI, De Rosa, E, Martinez, JO, Smid, CA, Buchanan, RM, Lee, SY, Srinivasan, S, Landry, M, Meyn, A, Tasciotti, E, Liu, X, Decuzzi, P & Ferrari, M 2010, 'Enabling individualized therapy through nanotechnology', Pharmacological Research, vol. 62, no. 2, pp. 57-89. https://doi.org/10.1016/j.phrs.2009.12.011
Sakamoto JH, van de Ven AL, Godin B, Blanco E, Serda RE, Grattoni A et al. Enabling individualized therapy through nanotechnology. Pharmacological Research. 2010 Aug 1;62(2):57-89. https://doi.org/10.1016/j.phrs.2009.12.011
Sakamoto, Jason H. ; van de Ven, Anne L. ; Godin, Biana ; Blanco, Elvin ; Serda, Rita E. ; Grattoni, Alessandro ; Ziemys, Arturas ; Bouamrani, Ali ; Hu, Ye ; Ranganathan, Shivakumar I. ; De Rosa, Enrica ; Martinez, Jonathan O. ; Smid, Christine A. ; Buchanan, Rachel M. ; Lee, Sei Young ; Srinivasan, Srimeenakshi ; Landry, Matthew ; Meyn, Anne ; Tasciotti, Ennio ; Liu, Xuewu ; Decuzzi, Paolo ; Ferrari, Mauro. / Enabling individualized therapy through nanotechnology. In: Pharmacological Research. 2010 ; Vol. 62, No. 2. pp. 57-89.
@article{219f2940eabb49c5856f58250de3f61e,
title = "Enabling individualized therapy through nanotechnology",
abstract = "Individualized medicine is the healthcare strategy that rebukes the idiomatic dogma of 'losing sight of the forest for the trees'. We are entering a new era of healthcare where it is no longer acceptable to develop and market a drug that is effective for only 80{\%} of the patient population. The emergence of {"}-omic{"} technologies (e.g. genomics, transcriptomics, proteomics, metabolomics) and advances in systems biology are magnifying the deficiencies of standardized therapy, which often provide little treatment latitude for accommodating patient physiologic idiosyncrasies. A personalized approach to medicine is not a novel concept. Ever since the scientific community began unraveling the mysteries of the genome, the promise of discarding generic treatment regimens in favor of patient-specific therapies became more feasible and realistic. One of the major scientific impediments of this movement towards personalized medicine has been the need for technological enablement. Nanotechnology is projected to play a critical role in patient-specific therapy; however, this transition will depend heavily upon the evolutionary development of a systems biology approach to clinical medicine based upon {"}-omic{"} technology analysis and integration. This manuscript provides a forward looking assessment of the promise of nanomedicine as it pertains to individualized medicine and establishes a technology {"}snapshot{"} of the current state of nano-based products over a vast array of clinical indications and range of patient specificity. Other issues such as market driven hurdles and regulatory compliance reform are anticipated to {"}self-correct{"} in accordance to scientific advancement and healthcare demand. These peripheral, non-scientific concerns are not addressed at length in this manuscript; however they do exist, and their impact to the paradigm shifting healthcare transformation towards individualized medicine will be critical for its success.",
keywords = "-Omic technologies, Implantable device, Individualized therapy, Nanomedicine, Nanoparticle, Nanotechnology, Nanovector, Personalized medicine, Regulatory process, Systems biology, Tissue engineering",
author = "Sakamoto, {Jason H.} and {van de Ven}, {Anne L.} and Biana Godin and Elvin Blanco and Serda, {Rita E.} and Alessandro Grattoni and Arturas Ziemys and Ali Bouamrani and Ye Hu and Ranganathan, {Shivakumar I.} and {De Rosa}, Enrica and Martinez, {Jonathan O.} and Smid, {Christine A.} and Buchanan, {Rachel M.} and Lee, {Sei Young} and Srimeenakshi Srinivasan and Matthew Landry and Anne Meyn and Ennio Tasciotti and Xuewu Liu and Paolo Decuzzi and Mauro Ferrari",
year = "2010",
month = "8",
day = "1",
doi = "10.1016/j.phrs.2009.12.011",
language = "English (US)",
volume = "62",
pages = "57--89",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Enabling individualized therapy through nanotechnology

AU - Sakamoto, Jason H.

AU - van de Ven, Anne L.

AU - Godin, Biana

AU - Blanco, Elvin

AU - Serda, Rita E.

AU - Grattoni, Alessandro

AU - Ziemys, Arturas

AU - Bouamrani, Ali

AU - Hu, Ye

AU - Ranganathan, Shivakumar I.

AU - De Rosa, Enrica

AU - Martinez, Jonathan O.

AU - Smid, Christine A.

AU - Buchanan, Rachel M.

AU - Lee, Sei Young

AU - Srinivasan, Srimeenakshi

AU - Landry, Matthew

AU - Meyn, Anne

AU - Tasciotti, Ennio

AU - Liu, Xuewu

AU - Decuzzi, Paolo

AU - Ferrari, Mauro

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Individualized medicine is the healthcare strategy that rebukes the idiomatic dogma of 'losing sight of the forest for the trees'. We are entering a new era of healthcare where it is no longer acceptable to develop and market a drug that is effective for only 80% of the patient population. The emergence of "-omic" technologies (e.g. genomics, transcriptomics, proteomics, metabolomics) and advances in systems biology are magnifying the deficiencies of standardized therapy, which often provide little treatment latitude for accommodating patient physiologic idiosyncrasies. A personalized approach to medicine is not a novel concept. Ever since the scientific community began unraveling the mysteries of the genome, the promise of discarding generic treatment regimens in favor of patient-specific therapies became more feasible and realistic. One of the major scientific impediments of this movement towards personalized medicine has been the need for technological enablement. Nanotechnology is projected to play a critical role in patient-specific therapy; however, this transition will depend heavily upon the evolutionary development of a systems biology approach to clinical medicine based upon "-omic" technology analysis and integration. This manuscript provides a forward looking assessment of the promise of nanomedicine as it pertains to individualized medicine and establishes a technology "snapshot" of the current state of nano-based products over a vast array of clinical indications and range of patient specificity. Other issues such as market driven hurdles and regulatory compliance reform are anticipated to "self-correct" in accordance to scientific advancement and healthcare demand. These peripheral, non-scientific concerns are not addressed at length in this manuscript; however they do exist, and their impact to the paradigm shifting healthcare transformation towards individualized medicine will be critical for its success.

AB - Individualized medicine is the healthcare strategy that rebukes the idiomatic dogma of 'losing sight of the forest for the trees'. We are entering a new era of healthcare where it is no longer acceptable to develop and market a drug that is effective for only 80% of the patient population. The emergence of "-omic" technologies (e.g. genomics, transcriptomics, proteomics, metabolomics) and advances in systems biology are magnifying the deficiencies of standardized therapy, which often provide little treatment latitude for accommodating patient physiologic idiosyncrasies. A personalized approach to medicine is not a novel concept. Ever since the scientific community began unraveling the mysteries of the genome, the promise of discarding generic treatment regimens in favor of patient-specific therapies became more feasible and realistic. One of the major scientific impediments of this movement towards personalized medicine has been the need for technological enablement. Nanotechnology is projected to play a critical role in patient-specific therapy; however, this transition will depend heavily upon the evolutionary development of a systems biology approach to clinical medicine based upon "-omic" technology analysis and integration. This manuscript provides a forward looking assessment of the promise of nanomedicine as it pertains to individualized medicine and establishes a technology "snapshot" of the current state of nano-based products over a vast array of clinical indications and range of patient specificity. Other issues such as market driven hurdles and regulatory compliance reform are anticipated to "self-correct" in accordance to scientific advancement and healthcare demand. These peripheral, non-scientific concerns are not addressed at length in this manuscript; however they do exist, and their impact to the paradigm shifting healthcare transformation towards individualized medicine will be critical for its success.

KW - -Omic technologies

KW - Implantable device

KW - Individualized therapy

KW - Nanomedicine

KW - Nanoparticle

KW - Nanotechnology

KW - Nanovector

KW - Personalized medicine

KW - Regulatory process

KW - Systems biology

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=77953686812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953686812&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2009.12.011

DO - 10.1016/j.phrs.2009.12.011

M3 - Review article

C2 - 20045055

AN - SCOPUS:77953686812

VL - 62

SP - 57

EP - 89

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 2

ER -